A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MxA / myxovirus resistance protein A

[Related PubMed/MEDLINE]
Total Number of Papers: 124
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MxA  (>> Co-occurring Abbreviation)
Long Form:   myxovirus resistance protein A
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases. ---
2019 Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. ASS, DM, MDA5, PFA, RIG-I
2019 Enterovirus infection and type 1 diabetes: unraveling the crime scene. EV, HLA-I, MDA5, PKR, RIG-I
2019 Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. CMAS, JDCBS, JDM, MSA
2019 FebriDx: A Rapid Diagnostic Test for Differentiating Bacterial and Viral Aetiologies in Acute Respiratory Infections. ARIs, CRP
2019 Human Antiviral Protein MxA Forms Novel Metastable Membraneless Cytoplasmic Condensates Exhibiting Rapid Reversible Tonicity-Driven Phase Transitions. ER, GFP, IFN, VSV
2019 Human Cervical Epithelial Cells Release Antiviral Factors and Inhibit HIV Replication in Macrophages. GBP5, HCEs, IFN, ISGs, MIP-1alpha, OAS-1, RANTES, SN, TLR
2019 Immunobiotic Strains Modulate Toll-Like Receptor 3 Agonist Induced Innate Antiviral Immune Response in Human Intestinal Epithelial Cells by Modulating IFN Regulatory Factor 3 and NF-kappaB Signaling. IECs, IFN-beta, IL-10, IL-1beta, IL-6, IL-8, IRF3, LAB, NF-kappaB, OSA1, RIG-I, TLR3, TNF-alpha
2019 Introducing a New Algorithm for Classification of Etiology in Studies on Pediatric Pneumonia: Protocol for the Trial of Respiratory Infections in Children for Enhanced Diagnostics Study. CAP, IRRID, TREND
10  2019 Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies. DM, NXP2
11  2018 A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. CRP, URIs
12  2018 Destabilized adaptive influenza variants critical for innate immune system escape are potentiated by host chaperones. ---
13  2018 Genomic Characterization of Lactobacillus delbrueckii TUA4408L and Evaluation of the Antiviral Activities of its Extracellular Polysaccharides in Porcine Intestinal Epithelial Cells. APS, EPS, IFN, IRF, NF-kappaB, PIE, TLR3
14  2018 Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population. CHC, CI, HCV, IFN, IL28B, OR
15  2018 Interferon-alpha-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells. CLEM, IFN
16  2018 Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activation. HCV, ISGs
17  2018 Neutralizing antibody production against Rebif and ReciGen in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability. EDSS, ELISA, IFN-beta, NAb, RRMS
18  2018 Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use. CRP, PCT, URI
19  2018 [Antiviral effects of IL-27 on HBV in HepG2.2.15 cells via inducing MxA by STAT1 signal transduction pathway]. HBcAg, HBV, IL-27, pSTAT1
20  2017 Aetiology of febrile pharyngitis in children: Potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection. GAS
21  2017 Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. IFNs, MHC, PD-L1, pSTAT1
22  2017 Detection of Host Response to Viral Respiratory Infection by Measurement of Messenger RNA for MxA, TRIM21, and Viperin in Nasal Swabs. TRIM21
23  2017 Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections. CRP, NPV, PPV, URIs
24  2017 Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers. HER2, HR, TILs, TLSs
25  2017 Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy. EDSS, IFN-beta, MS, RRMS
26  2017 Lateral flow immunoassay with upconverting nanoparticle-based detection for indirect measurement of interferon response by the level of MxA. LFIA, MS, UCNP
27  2017 MxA mRNA decrease preceding NAb detection in IFNbeta-treated MS patients. IFN-beta, MS, NAbs
28  2017 Myxovirus resistance protein A (MxA) polymorphism is associated with IFNbeta response in Iranian multiple sclerosis patients. MS
29  2017 Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNbeta. NAbs
30  2017 Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis. MS
31  2017 Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. DM, MAC, PFA
32  2017 The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. DM, IFN, PM, SLE
33  2016 Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. MS
34  2016 IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. APOBEC, ISGs
35  2016 Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses. HCV, IL-23, PBMCs, qRT-PCR, RVR, SOCS3
36  2016 MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. HLA, IFNs, TILs, TNBC
37  2016 MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients. ---
38  2016 Plasmacytoid Dendritic Cells and Type I Interferon Signature in Lichen Striatus. LP, LS, pDCs
39  2016 Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infection. 2'-5'-OAS, Gal-9, HCV, IFN, PBMCs, SOCS1, Tim-3, TLR3
40  2015 Association of Myxovirus Resistance Gene Promoter Polymorphism with Response to Combined Interferon Treatment and Progression of Liver Disease in Chronic HCV Egyptian Patients. CI, HCV, IFN, OR
41  2015 Diagnosis of viral infections using myxovirus resistance protein A (MxA). AUC, ROC, Se, Sp
42  2015 Induction of interferon-lamda contributes to TLR3 and RIG-I activation-mediated inhibition of herpes simplex virus type 2 replication in human cervical epithelial cells. 5'ppp dsRNA, HSV-2, IFN-lamda, IFN-lamda, IRF3, ISG56, ISGs, NIDA, TLRs
43  2015 Oligomerization and GTP-binding Requirements of MxA for Viral Target Recognition and Antiviral Activity against Influenza A Virus. IAV, NP
44  2015 Structural analysis of tumor-related single amino acid mutations in human MxA protein. IFN, Mx1
45  2015 Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. CXCL10, DUSP1, HCV, ISG15, ISGs, LV-shDUSP1, OAS1, PEG-IFN, phosho-STAT1, USP18
46  2015 Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability. IFN-beta, MS, NAb, TPE
47  2014 Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. IFN-beta, MS, Mx1, NAbs
48  2014 Association of functional polymorphisms in the MxA gene with susceptibility to enterovirus 71 infection. EV71, ORs, PBMCs, PCR-RFLP
49  2014 Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PCR
50  2014 Hepatitis C virus impairs TLR3 signaling and inhibits IFN-lamda 1 expression in human hepatoma cell line. HCV, IFN, ISG56, JFH-1, NS, OAS-1, TLR3
51  2014 Immunological changes and increased expression of myxovirus resistance protein a in thyroid tissue of patients with recent onset and untreated Graves' disease. GD, pDCs
52  2014 Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. IFNs, ISGs, RSV
53  2014 Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. APOBEC, IFNs, IL-32
54  2014 MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. EIA, IFN, pSS
55  2014 MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. IFNbeta
56  2014 TRIM5alpha and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. CNS, PBMCs
57  2013 Endogenous IFNgamma in chronic HCV genotype 4 patients treated with PEG-IFNalpha and ribavirin. HCV, HCV-4, IFN-gamma, PEG-IFN, SNP
58  2013 IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. HBeAg, HBsAg, HBV, IL-17A, IL-17R, IL-22, IL-22R, OAS
59  2013 Intracellular RNA recognition pathway activates strong anti-viral response in human mast cells. IFIT3, MDA5, RIG-1
60  2013 Methamphetamine inhibits Toll-like receptor 9-mediated anti-HIV activity in macrophages. D1R, IFN, IRF7, METH, MyD88, TLR9
61  2013 MxA transcripts with distinct first exons and modulation of gene expression levels by single-nucleotide polymorphisms in human bronchial epithelial cells. IFN, ISRE, SNPs
62  2013 Myxovirus resistance gene A (MxA) expression suppresses influenza A virus replication in alpha interferon-treated primate cells. cRNA, gRNA, ISGs, RT-PCR, siRNA
63  2013 Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. HCV, IFN-alpha, PBMCs, TLR
64  2013 Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. HCV, HSC, IRF7, JFH, OAS-1, RIG-I, SN, TLR3
65  2013 The myxovirus resistance A (MxA) gene -88G>T single nucleotide polymorphism is associated with prostate cancer. ISRE
66  2013 Upregulation of innate antiviral restricting factor expression in the cord blood and decidual tissue of HIV-infected mothers. A3G, ART, CB, HEU, IFN, MNCs, TRIM-5alpha, UN
67  2013 Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-beta. CHMP, EMA, MS, NAbs
68  2012 Global secretome characterization of herpes simplex virus 1-infected human primary macrophages. HSV-1, IFIT2, STAT1
69  2012 Long-term beneficial effect of protease inhibitors on the intrinsic apoptosis of peripheral blood mononuclear cells in HIV-infected patients. 7-AAD, ART, Bax, Bcl-2, FasL, IFN-alpha, Nef, NNRTI, PIs, TRAIL
70  2012 MxA expression induced by alpha-defensin in healthy human periodontal tissue. HGECs, IFNs, OAS, PKR, SLPI
71  2012 Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. HCV, IFN, ISGs, PKR, SOCS3
72  2011 Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. huTRIM5alpha, IFN, IFNs, PBMCs, TRIM
73  2011 Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. IFN
74  2011 Interferon-inducible antiviral protein MxA enhances cell death triggered by endoplasmic reticulum stress. ER, TM
75  2011 MxA RNA quantification in febrile patients who underwent hematopoietic cell transplantation for primary immunodeficiency. ---
76  2010 A monoclonal antibody specific to human myxovirus resistance protein A. ---
77  2010 Activation of brain macrophages/microglia cells in hepatitis C infection. HCV, IFN, IL-1alpha, IP-10, TNF-alpha
78  2010 Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. 2',5'-OAS, IFN-beta, IFNARs, PKR, VSV
79  2010 Inhibition of interferon-alpha-induced signaling by hyperosmolarity and hydrophobic bile acids. IFN-alpha, PKR
80  2010 Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. 2',5'-OAS, 5-FU, IFNAR, MHC, Rb
81  2010 Lentivirus-mediated expression of MxA in chicken spermatogonial stem cells. EGFP, SSCs
82  2010 Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. BDCA-1, DC, DM, IFN, mDCs, pDCs
83  2010 Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study. CPE, IFN-beta, MMP-9, MS, NAbs, TRU
84  2010 Preparation of polyclonal antibody against human MxA protein and its specificity to diversified myxovirus resistant protein A. ---
85  2010 Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. MS, NAb
86  2010 Significance of the myxovirus resistance A (MxA) gene -123C>a single-nucleotide polymorphism in suppressed interferon beta induction of severe acute respiratory syndrome coronavirus infection. SARS, SNPs
87  2010 Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. CELs, CI, HR, MS
88  2009 Antibodies against interferon-beta in multiple sclerosis. BAB, IFN-beta, mRNA, NAb, PCR, RRMS
89  2009 Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. IFIT1, IFN-beta, MS, NAbs, s.c, TRU
90  2009 Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. IFN, MS, NAbs
91  2009 Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. CPE, IFN-beta, MS, NAb
92  2009 Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. IFN-beta, MS, NAb
93  2009 Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta. IFN-beta, MP, NAbs, NC
94  2009 The haplotype of the MxA gene promoter is associated with hepatitis B virus infection in a Chinese population. CI, HBV, OR
95  2009 Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. AZA, IFN-beta, MP, MS, NAbs
96  2008 A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. DM, HMGB1, IBM, IFN-gamma, IL, IMACS, MAC, MHC, PM, TNF
97  2008 Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. HCV, IFN-alpha, IFN-beta
98  2008 Herpes simplex virus type 1 Us3 gene deletion influences toll-like receptor responses in cultured monocytic cells. HSV-1, IFN, TLR
99  2008 Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. IFN-alpha, pDC
100  2008 Induction of innate immune response and absence of subsequent tolerance to dsRNA in biliary epithelial cells relate to the pathogenesis of biliary atresia. BA, BECs, HIBECs, NF-kappaB, TLR, TRAIL